Literature DB >> 2548740

Differential interleukin-2 and interferon-gamma production by human lymphocyte cultures exceptionally resistant to Epstein-Barr virus immortalization.

J Gosselin1, J Menezes, G Mercier, G Lamoureux, D Oth.   

Abstract

Epstein-Barr virus (EBV) readily immortalizes human peripheral blood lymphocytes (PBL) in vitro. However, during the past several years, we found that PBL from two exceptional EBV-seropositive healthy adult individuals were refractory to immortalization by EBV. We report here a study aimed at learning about the immunobiological features which differentiate these EBV-resistant (R) PBL from others which are susceptible (S) to EBV immortalization. Results of this investigation indicate that: (a) Following EBV infection, R-PBL produced significantly higher amounts of interferon gamma (IFN-gamma) than S-PBL. There were however no differences in regard to interferon alpha production between these two types (R and S) of EBV-infected cultures. (b) R-PBL had a maximal interleukin-2 (IL-2) production by S-PBL occurred at least 48 hr later, i.e., at Day 7. (c) The percentage of non-B cells expressing the IL-2 receptor was also higher in EBV-infected R-PBL than S-PBL. (d) In contrast, expression of IL-2 receptors after EBV infection was higher on B cells from S-PBL than on B cells from R-PBL. Interestingly, no differences were noted in regard to IL-2 receptor expression between R-PBL and S-PBL treated with mitogens (i.e., phytohemagglutinin and pokeweed mitogen). (e) Finally, using anti-IL-2 and anti-IFN-gamma antibodies in EBV-infected R-PBL cultures, we were able to obtain EBV-induced immortalization of these cultures. Taken together, these results suggest that an early IL-2 synthesis and high IFN-gamma production by EBV-infected PBL play an important role against lymphocyte immortalization by EBV.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548740     DOI: 10.1016/0008-8749(89)90090-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

Review 1.  Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1.

Authors:  K W Moore; F Rousset; J Banchereau
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo.

Authors:  M W Hornef; H J Wagner; A Kruse; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

3.  Molecular characterization and determination of the coding capacity of the genome of equine herpesvirus type 2 between the genome coordinates 0.235 and 0.258 (the EcoRI DNA fragment N; 4.2 kbp).

Authors:  H J Rode; J J Bugert; M Handermann; P Schnitzler; R Kehm; W Janssen; H Delius; G Darai
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

4.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.

Authors:  P Vieira; R de Waal-Malefyt; M N Dang; K E Johnson; R Kastelein; D F Fiorentino; J E deVries; M G Roncarolo; T R Mosmann; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

5.  Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures.

Authors:  L Flamand; J Gosselin; M D'Addario; J Hiscott; D V Ablashi; R C Gallo; J Menezes
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Infection of peripheral blood mononuclear cells by herpes simplex and Epstein-Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor-alpha.

Authors:  J Gosselin; L Flamand; M D'Addario; J Hiscott; J Menezes
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.